Physician profile
Alan I Nussbaum
NPI 1982645529
$3,603.15
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $400 · 2021: $555 · 2022: $895 · 2023: $670 · 2024: $59.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.34 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $819.73 | 2019-2023 | Avsola, Amjevita, Enbrel |
| Abbvie INC. | $513.16 | 2019-2023 | |
| Janssen Biotech, INC. | $329.90 | 2019-2024 | Tremfya, Simponi Aria |
| Pfizer INC. | $291.97 | 2019-2023 | |
| Glaxosmithkline, LLC. | $243.47 | 2019-2023 | Benlysta |
| Ucb, INC. | $238.06 | 2019-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $194.10 | 2019-2022 | |
| Lilly USA, LLC | $191.06 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $117.82 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $88.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $85.85 | 2021-2022 | |
| Radius Health, INC. | $76.45 | 2019-2021 | |
| Genentech USA, INC. | $70.08 | 2019-2020 | |
| Genzyme Corporation | $58.53 | 2023 | |
| Horizon Therapeutics Plc | $58.23 | 2019-2023 | Krystexxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $45.54 | 2019-2023 | Ryaltris |
| Aurinia Pharma U.S., INC. | $45.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.26 | 2020 | |
| Depuy Synthes Sales INC. | $18.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Nussbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.